Treatment of Premenstrual Dysphoric Disorder

@article{Rapkin2013TreatmentOP,
  title={Treatment of Premenstrual Dysphoric Disorder},
  author={A. Rapkin and E. Lewis},
  journal={Women's Health},
  year={2013},
  volume={9},
  pages={537 - 556}
}
Premenstrual dysphoric disorder (PMDD) is comprised of a cluster of affective, behavioral and somatic symptoms recurring monthly during the luteal phase of the menstrual cycle. The disorder affects 3–8% of menstruating women and represents the more severe and disabling end of the spectrum of premenstrual disorders, which includes premenstrual syndrome and premenstrual aggravation of underlying affective disorder. Rigorous and specific diagnostic criteria for PMDD were specified in the… Expand

Paper Mentions

Premenstrual syndrome: etiology, diagnosis and treatment. A mini literature review
TLDR
Treatment of PMS often requires pharmacological interventions andSerotonergic antidepressants are the mainstay for improving both physical and mood symptoms, and Oral contraceptives are also effective for relieving physical symptoms. Expand
Eating disorders in premenstrual dysphoric disorder: a neuroendocrinological pathway to the pathogenesis and treatment of binge eating
TLDR
The findings lend supports to existing studies linking binge eating to hormonal changes in the mid-luteal phase of the menstrual cycle, and may help advance new treatment options for a selected, severely impaired group of females struggling with excessive appetite and binge eating due to fluctuations in ovarian activity. Expand
Exploring premenstrual dysphoric disorder (PMDD) in the work context: a qualitative study
  • C. Hardy, J. Hardie
  • Psychology, Medicine
  • Journal of psychosomatic obstetrics and gynaecology
  • 2017
TLDR
The most common symptoms women experience at work include difficulty in concentrating, self-doubt, paranoia, fatigue, tearfulness, a heightened sensitivity to the environment and people, outbursts, and finding social interaction particularly difficult during this premenstrual “episode” phase. Expand
Selective Serotonin Reuptake Inhibitors for Premenstrual Dysphoric Disorder
TLDR
Treatments that enhance serotonergic action improve premenstrual irritability and dysphoria with a rapid onset of action, suggesting a different mechanism of action than in the treatment of depression. Expand
A school-based survey of premenstrual dysphoric disorder-relationship with depression, anxiety, self-esteem and quality of life
Introduction: Premenstrual dysphoric disorder (PMDD) is a severe and debilitating form of Premenstrual syndrome (PMS) affecting women in their reproductive age. There is paucity of Indian research inExpand
Neuroimaging premenstrual dysphoric disorder: A systematic and critical review
TLDR
While white matter integrity remains uninvestigated, greater cerebellar grey matter volume and metabolism were observed in patients with PMDD, along with altered serotonergic and GABAergic neurotransmission. Expand
Assessment of N-acetylcysteine as an Alternative for the Treatment of the Premenstrual Dysphoric Disorder: A Randomized Clinical Trial
TLDR
Findings of the study are in favor of NAC use for the treatment of PMDD, with larger sample size and elongated duration of treatment and follow-ups strongly recommended. Expand
Premenstrual Dysphoric Disorder: Reviews of Studies in Malaysia, Measures Used, and Validation of the Daily Record of Severity of Problems
Premenstrual Dysphoric Disorder (PMDD) is the most severe form of Premenstrual Syndrome (PMS). It impacts the lives and productivity of women worldwide. The literature review found eight studiesExpand
Is Premenstrual Syndrome a Uterine Inflammatory Disease? Retrospective Evaluation of an Etiologic Approach
TLDR
Both PMS physical and psycho-affective symptoms respond to local anti-inflammatory and antibiotic treatment of the uterus, showing a stable improvement after the treatment has ended, suggesting that the clinical pattern of PMS can be explained as an inflammatory mediated response to uterine infectious or traumatic insults. Expand
Toxoplasma gondii Infection and Premenstrual Dysphoric Disorder: A Cross-Sectional Study
TLDR
Results of this first study on the association of T. gondii infection and clinical characteristics of premenstrual dysphoric disorder suggest that this infection might be linked to some symptoms of this disorder. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 246 REFERENCES
Premenstrual Dysphoric Disorder and Severe Premenstrual Syndrome in Adolescents
TLDR
Premenstrual syndrome can be ameliorated by education about the nature of the disorder, improving calcium intake, performing exercise and reducing stress, but to treat severe PMS or PMDD pharmacologic therapy is usually required. Expand
The pharmacologic management of premenstrual dysphoric disorder.
TLDR
Due to the unique pathophysiology of the disorder, the selective serotonin re-uptake inhibitors can be effectively administered intermittently, with dosing limited to the luteal phase of the cycle (2 weeks prior to menses). Expand
Diagnosis and treatment of premenstrual dysphoric disorder.
TLDR
Patients with mild to moderate symptoms of premenstrual syndrome may benefit from nonpharmacologic interventions such as education about the disorder, lifestyle changes, and nutritional adjustments, but those who fail to respond to more conservative measures may also require pharmacologic management. Expand
Duloxetine treatment for women with premenstrual dysphoric disorder: a single-blind trial.
TLDR
Duloxetine was effective and generally well tolerated in the treatment of PMDD and significant improvements were demonstrated by secondary measures, including reduction in self-rated functional impairment and improvement in quality of life. Expand
Duloxetine for premenstrual dysphoric disorder: a pilot study
TLDR
Duloxetine 60 mg/day was effective in reducing PMDD symptoms and generally well tolerated and the results appeared to be strong and consistent across measures. Expand
Update on research and treatment of premenstrual dysphoric disorder.
TLDR
Evidence suggests that individual sensitivity to cyclical variations in levels of gonadal hormones may predispose certain women to experience these mood, behavioral, and somatic symptoms in the week prior to menses. Expand
Premenstrual syndrome and premenstrual dysphoric disorder: quality of life and burden of illness
  • A. Rapkin, S. Winer
  • Medicine
  • Expert review of pharmacoeconomics & outcomes research
  • 2009
TLDR
This review will focus on the epidemiology, diagnosis, treatment outcomes, quality of life and burden of illness for premenstrual disorders. Expand
Symptomatic Improvement of Premenstrual Dysphoric Disorder With Sertraline Treatment: A Randomized Controlled Trial
TLDR
Serotonin reuptake inhibitors such as sertraline are useful therapeutic options for women with premenstrual dysphoria as reflected by symptomatic improvement and change in reported functional impairment. Expand
Pretreatment pattern of symptom expression in premenstrual dysphoric disorder.
TLDR
The results of this analysis found significant within-patient variability in the time-to-onset and offset of PMDD symptoms, as well as their duration, which may have treatment implications. Expand
A naturalistic study of paroxetine in premenstrual syndrome: efficacy and side-effects during ten cycles of treatment
TLDR
The rating of premenstrual irritability, depressed mood, increase in appetite, and anxiety/tension was markedly lower during treatment with paroxetine than before, and this reduction in symptoms appeared unabated for the entire treatment period. Expand
...
1
2
3
4
5
...